Lv2
140 积分 2024-06-28 加入
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
19天前
已完结
Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis
1个月前
已完结
Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study
1个月前
已完结
An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma
1个月前
已完结
The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer
2个月前
已完结
Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma
2个月前
已完结
Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer
2个月前
已完结
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
2个月前
已完结
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2
3个月前
已完结
皖公网安备34019202002308
